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Identity 
Other names: CGI-56, affixin, beta-parvin 
HGNC (Hugo): PARVB 
Location: 22q13.31 
Local order: PARVB is located telomeric to the 




Genethon marker D22S1171 is located at the 5' end of 
the gene (Mongroo et al., 2004). Genethon marker 
D22S1171 is located between exon 2 and exon 1A of 
the PARVB gene. 
The PARVA gene is located at 11p15.3. 
 
Figure A. Generation of transcript diversity by alternative promoter usage. Horizontal lines above the gene structure indicate human 
genomic DNA BAC clones. The NCBI accession numbers of the clones, and clone names (in brackets) are shown. Figure adapted from 
Mongroo et al., 2004.  
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Figure B. Human polyA
+ 
RNA Multiple Tissue Northern blot (Origene) probed with full-length PARVB1 cDNA probe radiolabeled to a 
specific activity of > 5 x 10
8
 cpm / mg (Johnstone C.N., unpublished). The two PARVB mRNA transcripts are indicated. The higher M.W. 
band most likely corresponds to non-specific hybridization (n/s). 
 
Description 
PARVB3/CLINT, which encodes the longer Parvin-
beta protein isoform is transcribed from promoter 1 and 
contains two additional 5' exons (exons 1 and 2) not 
present in PARVB1, and comprises 14 exons in total. 
PARVB1 encodes the shorter Parvin-beta protein 
isoform, is transcribed from promoter 1A, and 
comprises 13 exons in total. Both promoters contain 
CpG islands that span the transcription start sites. 
PARVB3/CLINT contains 70 unique N-terminal amino 
acids not present in the short isoform. (See figure A). 
Transcription 
As with PARVA, human PARVB mRNA expression is 
highest in heart, followed by skeletal muscle, where it 
localises to the sarcolemma (Yamaji et al., 2001; 
Matsuda et al., 2005). Both PARVB mRNA transcripts 
are essentially ubiquitously expressed (Korenbaum et 
al., 2001), but with lower expression in gastrointestinal 
tissues (stomach, small intestine, colon). (See figure B). 
Protein 
Description 
The major functional domains of Parvin-beta are two 
'atypical' calponin homology (CH) domains, termed 
CH1 (106 amino acids) and CH2 (107 amino acids). 
Each CH domain contains two actin binding sequences 
(ABS), although Parvin-beta has not been shown to 
bind actin directly (Korenbaum et al., 2001; Sepulveda 
and Wu, 2006). Parvin-beta physically interacts with 
Dysferlin and ARHGEF6 (alpha-PIX) through the CH1 
domain (Matsuda et al., 2005; Rosenberger et al., 2003) 
and with ILK and alpha-actinin through the CH2 
domain (Yamaji et al., 2001; Yamaji et al., 2004). 
Parvin-beta was also recently reported to directly 
interact with AKT (Kimura et al., 2010). 
Expression 
PARVB is essentially ubiquitously expressed. 
Localisation 
Parvin-beta localises to focal adhesions but also to the 
nucleus, which is most likely due to NLS motifs in the 
N-terminal region (Mongroo et al., 2004; Johnstone et 
al., 2008). Parvin-beta is incorporated into focal 
adhesions as part of the heterotrimeric 'IPP complex'. 
The ternary complex contains 1 molecule of integrin 
linked kinase (ILK), 1 Parvin isoform, and 1 PINCH 
(LIMS) isoform, (Legate et al., 2006). Binding of 
Parvin-alpha and Parvin-beta to the kinase domain of 
ILK is mutually exclusive (Zhang et al., 2004). 
Formation of the IPP complex also dictates total protein 
levels of each component, as any excess ILK, Parvin, 
or PINCH not incorporated into IPP is degraded in a 
proteasome-dependent manner (Fukuda et al., 2003). 
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Depiction of functional domains of Parvin-beta(long) and Parvin-beta(short). NLS, nuclear localization sequence; ABS, actin 
binding sequence; CH, calponin homology. Adapted from Sepulveda and Wu, 2006. 
 
Function 
Parvin-beta participates in focal adhesion dynamics 
through involvement in the IPP complex. The high 
expression levels in cardiac and skeletal muscle suggest 
important function(s) in these organs. In skeletal 
muscle, it binds dysferlin at the sarcolemma and thus 
may be involved with membrane repair (Yamaji et al., 
2001; Matsuda et al., 2005; Legate et al., 2006). Parvin-
beta and Parvin-alpha appear to negatively regulate the 
expression of each other (Zhang et al., 2004; Johnstone 
et al., 2008). Parvin-beta may modulate signalling 
through ILK as overexpression of Parvin-beta reduced 
AKT (S473) and GSK3beta (S9) phosphorylation in 
response to EGF stimulation (Mongroo et al., 2004). 
Parvin-beta was recently reported to directly interact 
with AKT (Kimura et al., 2010), which may explain its 
effects on AKT phosphorylation. Parvin-beta interacts 
with ARHGEF6 (alpha-PIX), an exchange factor for 
RAC1, thus implicating Parvin-beta in regulation of 
RAC signalling downstream of integrin engagement 
(Rosenberger et al., 2003). Finally, Parvin-beta may 
affect metabolic pathways through promotion of 
CDK9-mediated phosphorylation and activation of 
PPARgamma transcriptional activity in the nucleus 
(Johnstone et al., 2008). Interestingly, Parvb knockout 
mice were recently generated. Whilst constitutive Parva 
null mice feature kidney and cardiovascular defects and 
die between E10.5 and E14.5 (Lange et al., 2009; 
Montanez et al., 2009), constitutive Parvb null mice are 
viable (Wickström et al., 2010), although a detailed 
phenotypic analysis has not yet been described. 
Homology 
Human Parvin-beta is most closely related to Parvin-
alpha [75% identity with Parvin-beta(short) and 67% 
identity with Parvin-beta(long)] and more distantly to 
Parvin-gamma [41% identity with both Parvin-
beta(short) and Parvin-beta(long)]. 
Mutations 
Note 
No mutations reported to date. 
Germinal 
Germline SNPs are identified in the PARVB gene by 
direct sequencing of PCR products amplified from 
cDNA prepared from 16 primary ductal 
adenocarcinomasand adjacent normal mammary gland 
from the same patient. Two non-synonymous SNPs 
were identified, W37R, and E175K (Johnstone et al., 
manuscript in preparation).  
Somatic 
No somatic mutations were found in an analysis of 16 
breast adenocarcinomas as presented above (Johnstone 
et al., manuscript in preparation). According to the 
C.O.S.M.I.C. online database (Forbes et al., 2008), 171 
unique cancer samples have been analysed for 
alterations in the PARVB gene, with no somatic 
changes found. A breakdown of the samples analysed 
is given below. 
 





No. of Alleles 
A98C A/C Intron 1 98** n/a n/a 3/8 
W37R T/C Exon 2 252 37 W>R 3/8 
D150D C/T Exon 5 593 150 D>D 2/32 
E175K G/A Exon 6 666 175 E>K 2/32 
A223A C/T Exon 7 812 223 A>A 2/32 
G316G^ C/T Exon 12 1097 318 G>G 2/32 
F354F^ C/T Exon 13 1205 354 F>F 2/32 
 
† Relative to transcription start site 
‡ Relative to translation start site 
^ Occur as a haplotype 






Atlas Genet Cytogenet Oncol Haematol. 2011; 15(1)   37 
** Relative to splice site 
 
Cancer Type No. of Specimens Reference 
Breast 11 Sjöblom et al., 2006 
Glioma 23 Parsons et al., 2008 
Clear Cell Renal 101 Dalgliesh et al., 2010 
Colon 12 Sjöblom et al., 2006 
Lung (cell lines) 11 N/A 
Pancreas (cell lines) 1 N/A 
Mesothelioma (cell lines) 1 N/A 
Melanoma (cell lines) 6 N/A 
Urinary tract (cell lines) 2 N/A 





Parvin-beta mRNA levels are reduced in primary 
human ductal adenocarcinoma compared with adjacent 
normal mammary gland. PARVB mRNA levels are 
also reduced in MDA-MB-231 and MDA-MB-453 cell 
lines. Post-transcriptional downregulation of protein 
expression may also occur in cancer cells such as 
MCF7 (Mongroo et al., 2004). Ectopic Parvin-beta 
expression in MDA-MB-231 metastatic breast cancer 
cells increased adhesion and reduced invasion. Ectopic 
expression also reduced tumorigenicity of the same cell 
line in nude mice in vivo. Parvin-beta expression did 
not affect proliferation of the cells in vitro, but reduced 
Ki-67 staining was observed in Parvin-beta 
transfectants in vivo (Johnstone et al., 2008). Parvin-
beta overexpression was also reported to promote 
apoptosis in HeLa cervical cancer cells (Zhang et al., 
2004). 
Prognosis 
Association with prognosis has not been studied to 
date. 
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